Keith A. A. Fox, MB, ChB, FACC, and Deepak L. Bhatt, MD, MPH, FACC, discuss the Tuesday meeting highlights from ESC Congress 2015, including the MATRIX trial and the ODYSSEY trial. View full ESC Congress 2015 meeting coverage at ACC.org/ESC2015. Continue reading
Keith A. A. Fox, MB, ChB, FACC, and Deepak L. Bhatt, MD, MPH, FACC, discuss the Monday meeting highlights from ESC Congress 2015, including the PATHWAY 2 and PATHWAY 3 trials, the OPTIDUAL trial and the Long-Term DAPT trial. View full ESC Congress 2015 meeting coverage at ACC.org/ESC2015. Continue reading
I had the honor of representing the ACC at the “Global Meeting on Prevention of Cardiovascular Disease to Address the Shared Challenges of 25 by 25” hosted by the World Heart Federation (WHF) and the European Society of Cardiology (ESC) as part of ESC Congress 2015 taking place in London. The meeting brought together cardiovascular organizations from across the world to discuss the “25 x 25” global initiative, which strives to achieve a 25 percent relative reduction in overall mortality from non-communicable diseases (NCDs), including cardiovascular disease, cancer, diabetes or chronic respiratory disease, by 2025. Continue reading
The annual European Society of Cardiology (ESC) Congress not only provides opportunities to learn about the latest cardiovascular research from across Europe and the rest of the world, but it also creates a unique venue for cardiovascular leaders to come together to discuss opportunities for collaboration and innovation.
Over the course of the five-day meeting, I and other ACC leaders will have met with our counterparts from societies like ESC, the American Heart Association, the World Heart Federation and others; chaired several joint sessions with ESC touching on important trends in cardiovascular medicine; and given interviews with media from around the world addressing findings from the research being presented. In fact, just today, I had the privilege of chairing a Hotline Session presenting new research on Diabetes. Continue reading
The benefits of statin therapy in reducing the morbidity and mortality associated with atherosclerotic cardiovascular disease (ASCVD) are well documented; however, statins remain underutilized for both primary and secondary prevention. Two years ago the ACC launched its LDL: Address the Risk Initiative with the goal of closing this disparity in care and improving patient outcomes by increasing awareness of the gaps in lipid management, including the importance of managing LDL-related risks. Continue reading
It’s been a busy summer for U.S. Food and Drug Administration (FDA) news. Several key decisions made by the Agency and the courts in recent months are sure to impact medicine in the months and years to come.
Of course the big FDA headline in July was the Agency’s approval of the first proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor – Regeneron Pharmaceuticals’ Praluent (alirocumab) – for the treatment of patients with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in conjunction with maximally tolerated statin therapy and diet modification. The FDA is expected to make a decision about a second PCSK9 inhibitor – Amgen’s Repatha (evolocumab) – later this summer. This new class of lipid-lowering drugs has the potential to offer millions of patients with high LDL-C an alternative treatment option to statins, which have been associated with numerous side effects for decades. Continue reading
This post was authored by ACC President Kim Allan Williams Sr., MD, FACC.
Each August the ACC’s Board of Trustees comes together for a mid-year check-in on College activities and progress towards strategic goals. This meeting is also an important time for College leaders to make decisions relating to hot issues that have emerged since the last meeting in March.
This year’s meeting was no different, with ACC leaders and staff presenting on efforts to date around the College’s four strategic themes of population health, transformation of care, purposeful education, and member value and engagement. However, one of the hottest topics at this year’s meeting was the American Board of Internal Medicine’s (ABIM) controversial Maintenance of Certification (MOC) policies and how to move forward in a manner that best meets the needs of internal medicine physicians and the patients they serve. Continue reading
Doesn’t it feel good to be taken under some bigwig’s wing and be guided on a path that might otherwise be difficult to find on your own? Wouldn’t it be great if someone could show you how to do something with great success without all the typical sputtering? Can you imagine being associated with someone so well known it brings you, the little-known-newbie, into the spotlight too?
If you answered yes to any of these, you have begun to see the magic of what is known as mentorship. Mentorship takes many forms – from a senior partner telling you how to impress referring physicians, to a professor emeritus giving you the hints you need to get that National Institutes of Health grant, to a middle-career clinician teaching you how to open those chronic total occlusions – and many others. In short, it is building “upon the shoulders” of those who came before – the “giants” in our career. Continue reading